Regenerx Biopharma (RGRX) Receives EPO Notice of Intent to Grant Patent Related to Thymosin Beta 4
- Wall St. edges higher as earnings gather pace
- Alibaba (BABA) Tops Q3 EPS by 17c, Revenues Rise 54%
- DuPont (DD) Tops Q4 EPS by 9c; Sees Merger Closing in First Half
- Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; Guides Modestly Below the Street
- Pre-Open Stock Movers 01/24: (MPSX) (IIVI) (AKS) Higher; (FSM) (OCUL) (VZ) Lower (more...)
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) announced that it has received notice of Intent to Grant a patent from the European Patent Office for the treatment of patients with MS. The patent covers use of the Company's proprietary molecule Thymosin beta 4 (Tβ4) in a composition for treating or reducing deterioration of, injury or damage to tissue due to MS. The patent expiry is January 13, 2026.
"This patent expands our exclusivity for the potential administration of RGN-352 in patients with multiple sclerosis in key countries in Europe and broadens our patent portfolio related to the systemic use of RGN-352 for CNS and neurodegenerative disorders. We are pleased patent applications for our technologies, some of which were initially filed years ago as part of our intellectual property strategy, continue to be granted throughout the world," stated J.J. Finkelstein, RegeneRx's president and chief executive officer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cellectar Biosciences (CLRB) Announces US Patent Granted for CLR 131 and CLR 125
- Flex Pharma (FLKS) to Prioritize Phase 2 Clinical Programs in Severe Neurological Diseases
- Asterias Bio (AST) Announces Efficacy Results at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical SCI
Create E-mail Alert Related CategoriesCorporate News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!